A Resolution has been put forward for consideration at the National AGM that “The Society should make people with MS aware that Low Dose Naltrexone (LDN)  is a treatment option for MS and use their influence to make it readily available on the NHS” raised at the suggestion of Simon Gillespie.  Proposed by Bob Baxter, seconded by Heather Fairweather with David Taylor as Speaker at the AGM.

If LDN were tested and proven to stop MS as is suggested by the late Dr. Bihari along with others, it would be the cheapest and most effective treatment available today.

The clinical experience of many doctors and literally thousands of patients over the last 25 years is an acknowledgement to just that.

Most treatments are not licensed for MS

Support this resolution, raised at the suggestion of Simon Gillespie, and ensure via the societies democratic processes that they are able to put the interests of people with MS uppermost for those would like to try this treatment.

a key outcome of the consultation on the strategy was for the Society to increase the number of staff working locally and we have done so. The remaining 125 staff, based at the Society's offices in London, Edinburgh, Cardiff and Belfast undertake the following functions: • Fundraising and supporter and membership administration

• Finance, HR, IT and other services

• Management of the Society's research portfolio

• Policy and campaigning activities

• Operational management, including individual support and nurse grants, professional education activities

• Information provision (MS Essentials, website etc)

• PR and media activities

The Society's latest published annual report and accounts (2007) show an efficient organisation with low "overhead" costs in

comparison to similar charities, and as you can see the vast majority of the Society's staff are employed in delivering our

strategic aims. I hope this is helpful. Please let me know if you need any further information.

Yours sincerely

Simon Gillespie   Chief Executive